ProMIS shares positive early data for Alzheimer’s drug as larger trial advances

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

ProMIS presented data at the Alzheimer’s Association International Conference, showing a dose-dependent reduction in detectable amyloid-beta oligomers in cerebrospinal fluid at three and 29 days after a single dose of PMN310 in its Phase 1a healthy volunteer study (NCT06105528).

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE